Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Mads Emil Bjørn & Hans Carl Hasselbalch. (2017) Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib. Expert Review of Hematology 10:5, pages 393-404.
Read now
Read now
Adam R. Leman, Jayaraju Dheekollu, Zhong Deng, Seung Woo Lee, Mukund M. Das, Paul M. Lieberman & Eishi Noguchi. (2012) Timeless preserves telomere length by promoting efficient DNA replication through human telomeres. Cell Cycle 11:12, pages 2337-2347.
Read now
Read now
Articles from other publishers (11)
Abhik Chakraborty, Souvick Roy, Manoor Prakash Hande & Birendranath Banerjee. (2023) Telomere attrition and genomic instability in unexplained recurrent pregnancy loss in humans: A preliminary study. Mutation Research/Genetic Toxicology and Environmental Mutagenesis 886, pages 503580.
Crossref
Crossref
Mohamed E. Suliman, Mohammed G. A. Ansari, Mohamed A. Rayis, Muaawia A. Hamza, Abdullah A. Saeed, Abdul Khader Mohammed & Nasser M. Al-Daghri. (2021) Telomere length and telomere repeat-binding protein in children with sickle cell disease. Pediatric Research 91:3, pages 539-544.
Crossref
Crossref
Xiaobo Fan, Yunxia Zhu, Naixin Wang, Bing Zhang, Cui Zhang & Yanan Wang. (2021) Therapeutic Dose of Hydroxyurea-Induced Synaptic Abnormalities on the Mouse Spermatocyte. Frontiers in Physiology 12.
Crossref
Crossref
Hisashi Miura, Saori Takahashi, Takahiro Shibata, Koji Nagao, Chikashi Obuse, Katsuzumi Okumura, Masato Ogata, Ichiro Hiratani & Shin-ichiro Takebayashi. (2020) Mapping replication timing domains genome wide in single mammalian cells with single-cell DNA replication sequencing. Nature Protocols 15:12, pages 4058-4100.
Crossref
Crossref
Jonathan Munera López, Agustina Ganuza, Silvina S. Bogado, Daniela Muñoz, Diego M. Ruiz, William J. SullivanJr.Jr., Laura Vanagas & Sergio O. Angel. (2019) Evaluation of ATM Kinase Inhibitor KU-55933 as Potential Anti-Toxoplasma gondii Agent. Frontiers in Cellular and Infection Microbiology 9.
Crossref
Crossref
Iben Onsberg Hansen, Anders Lindholm Sørensen & Hans Carl Hasselbalch. (2017) Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms. European Journal of Haematology 98:1, pages 75-84.
Crossref
Crossref
Shahida A. Khan, Ghazi Damanhouri, Ashraf Ali, Sarah A. Khan, Aziz Khan, Ahmed Bakillah, Samy Marouf, Ghazi Al Harbi, Saeed H. Halawani & Ahmad Makki. (2016) Precipitating factors and targeted therapies in combating the perils of sickle cell disease--- A special nutritional consideration. Nutrition & Metabolism 13:1.
Crossref
Crossref
Yiming Lu, Waiian Leong, Olivier Guérin, Eric Gilson & Jing Ye. (2013) Telomeric impact of conventional chemotherapy. Frontiers of Medicine 7:4, pages 411-417.
Crossref
Crossref
Nancy S. Green & Sandra Barral. (2011) Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease. Pediatric Blood & Cancer 56:2, pages 177-181.
Crossref
Crossref
Jing Zhou, Zhong Deng, Julie Norseen & Paul M. Lieberman. (2010) Regulation of Epstein-Barr Virus Origin of Plasmid Replication (OriP) by the S-Phase Checkpoint Kinase Chk2. Journal of Virology 84:10, pages 4979-4987.
Crossref
Crossref
Paola Sebastiani, Nadia Solovieff, Stephen W. Hartley, Jacqueline N. Milton, Alberto Riva, Daniel A. Dworkis, Efthymia Melista, Elizabeth S. Klings, Melanie E. Garrett, Marilyn J. Telen, Allison Ashley‐Koch, Clinton T. Baldwin & Martin H. Steinberg. (2009) Genetic modifiers of the severity of sickle cell anemia identified through a genome‐wide association study. American Journal of Hematology 85:1, pages 29-35.
Crossref
Crossref